AI Summary & Key Takeaways
AI InsightIn conclusion, although the long term follow-up results are not available, imatinib seems to be a well tolerated and efficient therapy for CML patients.
📌 3 Key Takeaways
Abstract
Imatinib mesylate is an inhibitor of the BCR-ABL tyrosine kinase, the putative cause of chronic myelogenous leukemia (CML). It was observed in clinical trials that as a targeted therapy, it has demonstrated high levels of efficacy both clinically and cytogenetically. In this study ten patients with chronic phase CML diagnosis that were treated with imatinib therapy in our hematology department were evaluated retrospectively. It was established that all the patients tolerated the drug well and most of the unresponsive patients to previous therapy achieved hematologic and cytogenetic response. In conclusion, although the long term follow-up results are not available, imatinib seems to be a well tolerated and efficient therapy for CML patients.
Özet
İmatinib mesilat, kronik miyeloid löseminin (KML) etkeni olduğu ifade edilen BCR-ABL tirozin kinazın inhibitörüdür. Klinik çalışmalarda, hedefe yönelik tedavi olarak, yüksek düzeyde klinik ve sitogenetik etkinlik gösterdiği gözlenmiştir. Bu çalışmada Hematoloji Bilim Dalında imatinib ile tedavi edilen on kronik faz KML'li olgu retrospektif olarak değerlendirildi. Tüm hastaların tedaviyi iyi tolere ettiği ve önceki tedaviye yanıtsız hastalarda hematolojik ve sitogenetik cevabın oluştuğu tespit edildi. Sonuç olarak, uzun dönemli takip verileri henüz olmamasına rağmen KML'li hastalarda imatinib iyi tolere edilen ve etkin bir tedavi yöntemi gibi görünmektedir.